Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the safety and efficacy of Vismed®, a special eye drop
containing sodium hyaluronate, in the treatment of dry eye syndrome. Vismed® is being
compared to another eye drop, identical in composition except that it does not contain the
active ingredient, sodium hyaluronate. This eye drop is designed as the "vehicle." Some
subjects are to receive Vismed® treatment, while others are to receive the vehicle; the
assignment of subjects to receive either Vismed or vehicle is to be random. The two-week
treatment phase is followed by a one week follow-up period to evaluate safety of Vismed®.
Phase:
Phase 3
Details
Lead Sponsor:
Lantibio
Collaborators:
River Plate Biotechnology, Inc. Rx Development Resources, LLC